Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in patients with haematological diseases treated with anti-CD20 antibodies: An observational study

In clinical trials, mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown remarkable efficacy and safety in healthy participants. However, patients receiving anti-CD20 antibodies, such as rituximab or obinutuzumab (R/Obi), have been shown to have a poor humoral response to mRNA vaccines, although the response improves gradually if more time has elapsed. R/Obi exerts an immunosuppressive effect through B-cell depletion, which could explain the impaired response to mRNA vaccines. The factors related to vaccine ineffectiveness in patients receiving R/Obi have not been fully investigated. Therefore, this study aimed to assess the effectiveness and safety of COVID-19 mRNA vaccines in patients who had received R/Obi, and the factors associated with an impaired humoral response.

Patients and healthy volunteers were recruited in June and July 2021. The Institutional Review Board of Kobe City Medical Center General Hospital approved the study. Informed consent was obtained from all participants. Blood samples were collected 14–90 days after the second dose of vaccine. The primary end-point was the proportion of participants who acquired IgG antibodies to the receptor-binding domain in the S1 subunit of the SARS-CoV-2 spike protein (anti-S1 IgG antibodies). We evaluated humoral responses in participants who received R/Obi within less than 6, 6–9, 9–12, or more than 12 months prior to vaccination. To identify...
**TABLE 1** Characteristics of study participants

|                                | Patients (N = 148) | Healthy volunteer (N = 38) |
|--------------------------------|--------------------|---------------------------|
| **Age, median (IQR), years**   | 71 (64, 77)        | 28 (25, 40)               |
| **Sex, n (%)**                 |                    |                           |
| Male                           | 71 (48%)           | 9 (24%)                   |
| Female                         | 77 (52%)           | 29 (76%)                  |
| **Vaccine**, n (%)             |                    |                           |
| BNT162b2                       | 135 (91%)          | 38 (100%)                 |
| mRNA-1273                      | 13 (8.8%)          | 0 (0%)                    |
| **IgG, median (IQR), mg/dl**   |                    |                           |
| >700 mg/dl, n (%)              | 116 (78%)          | 38 (100%)                 |
| ≤700 mg/dl, n (%)              | 32 (22%)           | 0 (0%)                    |
| **IgA, median (IQR), mg/dl**   |                    |                           |
| >80 mg/dl, n (%)               | 117 (79%)          | 38 (100%)                 |
| ≤80 mg/dl, n (%)               | 31 (21%)           | 0 (0%)                    |
| **IgM, median (IQR), mg/dl**   |                    |                           |
| >40 mg/dl, n (%)               | 97 (66%)           | 37 (97%)                  |
| ≤40 mg/dl, n (%)               | 51 (34%)           | 1 (2.6%)                  |
| **WBC, median (IQR) x 10^3/μl**| 4.7 (3.9, 6.1)    | 6.156 (5.326, 7.251)     |
| **Lymphocytes, median (IQR) x 10^3/μl** | 1.339 (0.936, 1.718) | 1.393 (1.164, 1.736)     |
| >1.0 x 10^3/μl, n (%)          | 105 (71%)          | 34 (89%)                  |
| ≤1.0 x 10^3/μl, n (%)          | 43 (29%)           | 4 (11%)                   |
| **B cells, median (IQR)/μl**   | 138 (0, 266)       | 151 (113, 212)            |
| **B-cell fraction, n (%)**     |                    |                           |
| 0%                             | 43 (29%)           | 0 (0%)                    |
| 0%–3%                          | 6 (4.0%)           | 0 (0%)                    |
| >3%                            | 99 (67%)           | 38 (100%)                 |
| **T cells, median (IQR)/μl**   | 847 (569–1068)     | 956 (785–1239)            |
| **CD4+ T cells, median (IQR)/μl** | 378 (224–514)    | 519 (451–692)             |
| >0.4 x 10^3/μl, n (%)          | 68 (46%)           | 33 (87%)                  |
| ≤0.4 x 10^3/μl, n (%)          | 80 (54%)           | 5 (13%)                   |
| **NK cells, median (IQR)/μl**  | 210 (122–364)      | 207 (168–313)             |
| **Diseases, n (%)**            |                    |                           |
| DLBCL, NOS                     | 50 (34%)           | N/A                       |
| FL                             | 49 (33%)           |                           |
| MALT                           | 11 (7.4%)          |                           |
| MCL                            | 8 (5.4%)           |                           |
| LPL/WM                         | 7 (4.7%)           |                           |
| SMZL                           | 4 (2.7%)           |                           |
| BCL unclassifiable             | 4 (2.7%)           |                           |

**Disease status, n (%)**

- Complete remission: 107 (72%)
- Not in complete remission: 15 (10%)
- On active therapy: 26 (18%)

**Time from last anti-CD20 antibody treatment to vaccination, median (IQR), days**

- <6 months: 43 (29%)
- 6–9 months: 9 (6.1%)
- 9–12 months: 6 (4.1%)
- >12 months: 90 (61%)

**Time from second vaccination to serological assessment, median (IQR), days**

- 44 (29–66)
- 79 (75–81)

**Abbreviations:** BCL, B-cell lymphoma; BL, Burkitt lymphoma; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; IQR, interquartile range; ITP, idiopathic thrombocytopenic purpura; IVLBCL, intravascular large B-cell lymphoma; LPL, lymphoplasmacytic lymphoma; MALT, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; N/A, not applicable; NK, natural killer; NOS, not otherwise specified; PCNSL, primary central nervous system lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; R/Obi, rituximab or obinutuzumab; SLL, small lymphocytic lymphoma; SMZL, splenic marginal zone lymphoma; TTP, thrombotic thrombocytopenic purpura; WBC, white blood cells; WM, Waldenström's macroglobulinaemia.

*Three patients were excluded from the final analysis: one did not complete two vaccination doses due to stroke after the first vaccination and two were lost during follow-up due to disease progression.*

*Participants received two doses of mRNA vaccine as recommended (21 and 28 days apart for BNT162b2 and mRNA-1273, respectively, except two patients who received the second dose of BNT162b2 vaccine after 31 days, and one patient who received the second dose of BNT162b2 vaccine after 37 days.*

*Eight patients receiving ongoing R/Obi maintenance therapy were included. None of them exhibited a humoral response or detectable B cells.*
factors contributing to higher anti-S1 antibody titres, we investigated lymphocyte subsets including the CD19-positive B-cell fraction. The antibody response in patients whose B-cell fractions of total lymphocytes were 0%, 0%–3% or more than 3% was assessed to estimate the minimal proportion of B cells required to induce a humoral response following B-cell reconstitution. The inclusion and exclusion criteria, details of the data, kit used for antibody detection, and statistical issues are described in the Supporting Information.

A total of 151 patients with haematological diseases who had received R/Obi, and 38 healthy volunteers were included in the study. Three patients were excluded from the final analysis (Table 1). A positive antibody response to the vaccine was observed in 93/148 patients (64%) and in all 38 healthy controls. The median anti-S1 IgG titre was 98 [interquartile range (IQR) 0–576] and 499 (IQR 311–826) BAU/ml in the patients and controls, respectively. Among the seropositive patients, 40 (43%) were weak responders (anti-S1 IgG titres < 260 BAU/ml). Based on the results of subgroup analysis (Figures S1 and S2), we set the optimal cut-off at nine months from the last administration of R/Obi and 3% B cells. According to this cut-off, 91.7% of patients receiving R/Obi earlier than in the previous nine months achieved seropositivity, whereas only 11.5% of patients receiving R/Obi within nine months did so. Similarly, 90 patients (89.8%) with more than 3% B cells achieved a seropositive response, while 12% of those with 3% or fewer B cells were seronegative. The combined humoral response to time and B-cell fraction is shown in Figure 1. Of note, patients receiving the last R/Obi within nine months did not exhibit a humoral response even with more than 3% B cells and, conversely, those receiving R/Obi more than nine months earlier but still in a B-cell-depleted state displayed a poor response (Figure 1). Hence, both time from the last R/Obi treatment to vaccination and B-cell reconstitution were important for a humoral response. Details of adverse events and other subgroup analyses are available in the supplementary material (Figures S3 and S4). During the observation period, four cases of symptomatic COVID-19 (one severe and two mild cases in weak and non-responders, and one mild case in a responder) were recorded.

Some guidelines and several prospective studies recommend providing vaccination no earlier than six months after the last administration of B-cell-depleting therapy due to expected impaired humoral response. The underlying causes of poor humoral response to vaccination in patients with B-cell malignancies are attributed to both disease-related immune dysregulation and therapy-related immunosuppression. In patients treated with R/Obi, the depletion of B cells, which can last for six months, plays an essential role because B cells drive serologic responses. B-cell reconstitution resumes gradually after approximately 6–9 months, in parallel with the onset of seroconversion. Our study identified a threshold of 3% B cells as a predictor of the humoral response.

Two findings should be noted. First, patients failed to show a humoral response if the last R/Obi treatment was within the previous nine months, despite detectable B cells. Second, patients who received their last R/Obi more than nine months earlier, failed to show a humoral response if they did not possess sufficient B cells. Therefore, to accurately estimate vaccine effectiveness in patients receiving R/Obi, a combination of time from the last R/Obi administration and peripheral B-cell fraction (>3%) should be considered.

Administration of a third dose of mRNA vaccine to immunodeficient patients is being promoted in developed countries. However, a single-centre prospective study revealed a low seroconversion rate of only 18.2% in non-responders who had been exposed to rituximab and received a third dose. In this study, the median interval between the second and third vaccinations was 69 days, which is too short for adequate B-cell recovery. Therefore, allowing a period of six or nine months before the third dose while implementing strict protective measures, such as wearing masks and social distancing, may benefit the humoral response for non-responders and weak responders who received R/Obi. The use of pre-exposure prophylaxis to the monoclonal tixagevimab–cilgavimab antibody combination was also promising in this group.

This study has several limitations. First, the number of patients was relatively small and regimens used in combination with R/Obi were heterogeneous. Therefore, the potential impact of medications other than R/Obi on the humoral response should be considered. Second, although we excluded participants with reported COVID-19, some participants may have had asymptomatic infections, which might have interfered with the results. Third, we did not assess the cellular immune response.

In summary, we confirmed the safety and the lower effectiveness of mRNA vaccines among patients who received anti-CD20 therapy. A combination of time from the last R/Obi treatment and peripheral B-cell fraction (>3%) can help predict a humoral response to mRNA vaccines.

ACKNOWLEDGEMENTS
The authors would like to thank the nurses at the Haematology Department and laboratory staff at the Clinical Laboratory Department and LSI Medience Laboratory of Kobe City Medical Center General Hospital.

CONFLICT OF INTEREST
The authors have no financial or proprietary interest in any material discussed in this article.

AUTHOR CONTRIBUTIONS
Masashi Nishikubo and Yoshimitsu Shimomura initiated the trial, designed the study, and analysed the data. Masashi Nishikubo wrote the manuscript and Yoshimitsu Shimomura supervised the statistical analysis and manuscript writing, editing, and review. Hayato Maruoka, Seiko Nasu, Tomomi Nishioka and Kenji Sakizono performed, managed, and reported the measurements of anti-SARS-CoV-2 antibodies and other related laboratory data. Naoki Okada, Daishi
Nakagawa, Kimimori Kamijo, Hiroharu Imoto, Ryusuke Yamamoto, Yuya Nagai, Nobuhiro Hiramoto, Satoshi Yoshioka, Noboru Yonetani, Akiko Matsushita and Takayuki Ishikawa collected data and provided patient information. Yoshimitsu Shimomura and Takayuki Ishikawa coordinated the project and edited the manuscript. Chisato Miyakoshi provided comments on statistical analysis. Asako Doi provided comments on epidemiology and infection control. All authors have read and approved the final manuscript.

FUNDING INFORMATION
This work was supported by a grant from the "Kasahara Cancer Research Fund", Japan.

CLINICAL TRIAL REGISTRATION
This study was registered with the University Hospital Medical Information Network (UMIN) in Japan (UMIN000046043).

PATIENT CONSENT STATEMENT
Written informed consent was obtained from all study participants.

DATA AVAILABILITY STATEMENT
The datasets generated and/or analysed during the current study are available from the corresponding author upon reasonable request.

FUNDING INFORMATION
This work was supported by a grant from the "Kasahara Cancer Research Fund", Japan.

CLINICAL TRIAL REGISTRATION
This study was registered with the University Hospital Medical Information Network (UMIN) in Japan (UMIN000046043).

PATIENT CONSENT STATEMENT
Written informed consent was obtained from all study participants.

DATA AVAILABILITY STATEMENT
The datasets generated and/or analysed during the current study are available from the corresponding author upon reasonable request.

Masashi Nishikubo1
Yoshimitsu Shimomura1,2
Hayato Maruoka3
Seiko Nasu3
Tomomi Nishioka3
Kenji Sakizono3
Satoshi Mitsuyuki3
Tomoyo Kubo1
Naoki Okada1
Daishi Nakagawa
Kimimori Kamijo
Hiroharu Imoto3
Ryusuke Yamamoto1
Yuya Nagai1
Nobuhiro Hiramoto1
Satoshi Yoshioka1
Noboru Yonetani1
Akiko Matsushita1
Chisato Miyakoshi5
Asako Doi6
Takayuki Ishikawa1

1Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
2Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Osaka, Japan
3Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan
4LSI Medience Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan
5Department of Research Support, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital, Kobe, Japan
6Department of Infectious Diseases, Kobe City Medical Center General Hospital, Kobe, Japan

Correspondence
Yoshimitsu Shimomura, Department of Haematology, Kobe City Medical Center General Hospital, 2–1–1 Minami-machi, Minatojima, Chuo-ku, Kobe, Hyogo 650–0047, Japan.
Email: shimomura_0119@yahoo.co.jp

KEYWORDS
BNT162b2, COVID-19, haematological disorders, mRNA-1273, obinutuzumab, rituximab

ORCID
Masashi Nishikubo https://orcid.org/0000-0002-6183-8910
Yoshimitsu Shimomura https://orcid.org/0000-0003-1018-9508
Hiroharu Imoto https://orcid.org/0000-0002-2616-6311

REFERENCES
1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.
3. Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583–92.
4. Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood. 2021;138(9):811–4.
5. Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Ravà L, et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol. 2016;27(6):1811–22.
6. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.
7. Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5(12):2624–43.
8. Simon D, Tascilar K, Fagni F, Schmidt K, Könneke G, Kleyer A, et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Ann Rheum Dis. 2020;79(1):39–52.
9. National Institutes of Health. The COVID-19 Treatment Guidelines Panel’s statement on tixagevimab plus cilgavimab (Evusheld) for pre-exposure prophylaxis for SARS-CoV-2 infection [Internet]. Bethesda, Maryland: National Institutes of Health. [updated 1 Feb 2022; cited 27 Feb 2022]. https://www.covid19treatmentguidelines.nih.gov/
10. Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.